Ready-to-use, fast, consistent and automated algorithm for clinical decision support
An intelligent and insightful digital pathology solution requires image analysis tools that empower pathologists to confidently and objectively assess whole tissue slide images. The algorithm is indicated for use as an aid in identifying patients for treatment with therapies with the ≥ 50% PD-L1 TC positivity cutoff in accordance with the approved therapeutic product labeling.
Validated on the VENTANA PD-L1 (SP263) Assay, for use within Roche uPath enterprise software.
Pathologist-trained artificial intelligence algorithm for quick image analysis.
Actionable assessment of scanned slide images that are objective and reproducible, aiding in informing on potential treatment strategies.
Reference: uPath PD-L1 (SP263) image analysis for Non-Small Cell Lung Cancer Algorithm Guide
uPath PD-L1 (SP263) image analysis, NSCLC (CE-IVD) is not yet commercially avaiable in Sweden